Amgen (AMGN) Q3 2026 Earnings Call Transcript

Amgen reported Q3 2026 revenue of $10.4 billion, up 8% year over year, and non-GAAP EPS of $6.45, up 14%; it raised full-year revenue guidance to $38.9 billion-$39.7 billion and non-GAAP EPS guidance to $22.90-$23.70. Growth included Repatha sales up 37% to $1.1 billion and IMDELLTRA sales more than doubling to $406 million, alongside positive Phase III results in three programs. Headwinds included declining Prolia and XGEVA sales amid biosimilar competition and an FDA request for voluntary withdrawal of TAVNEOS; the quarterly dividend rose 6% to $2.52 per share.

Analysis

AMGN’s key valuation question is whether growth from newer franchises can outpace erosion in mature biologics—not whether this quarter’s execution was strong. The portfolio’s breadth reduces dependence on any single launch, but Prolia/XGEVA biosimilar losses are a live test of whether that diversification offsets declining legacy cash flows. Amgen’s own biosimilar expansion may also intensify price competition across the category; growth in that business is not automatically equivalent to durable margin growth.

Near term, the raised outlook is supportive, but the expected Q4 expense step-up could limit incremental earnings leverage and temper a post-call rerating. Over 1–3 months, the more material catalysts are regulatory and guideline progress for IMDELLTRA in earlier-line small-cell lung cancer and the pending symptomatic Sjögren’s readout. The survival result could expand treatment duration and addressable patients, but uptake depends on approval, clinical adoption, and manageable treatment logistics; company enthusiasm is not yet revenue evidence. Over 6–18 months, MariTide has substantial upside optionality, but monthly dosing and tolerability remain hypotheses to validate in Phase III, while manufacturing investment creates execution risk before demand is established.

Contrarian angle: investors may overvalue headline growth-driver momentum while underweighting the cash-flow drag from biosimilar erosion and the risk that pipeline expectations become capitalized well ahead of launch. Conversely, treating MariTide as a simple obesity-megatrend asset misses the potential differentiation of dosing frequency—but that advantage is unproven until comparative efficacy, tolerability, access, and persistence data emerge.

Key Decisions for Investors

• Maintain a measured long bias in AMGN rather than chase the earnings reaction; consider adding on weakness if guidance is maintained and legacy-product erosion does not accelerate. No valuation or price-level data were supplied to justify a target.
• Treat IMDELLTRA as a 1–3 month catalyst watch, not a booked sales step-up: monitor FDA filing/approval timing, label monitoring requirements, and guideline adoption. Reassess if regulatory timing slips or clinical use fails to broaden beyond experienced centers.
• Track Prolia and XGEVA volume and net-price trends against growth in newer products. Faster erosion without offsetting portfolio growth or margin resilience would falsify the diversification thesis and argue for reducing exposure.
• Keep MariTide exposure conditional on Phase III efficacy, discontinuation/tolerability, and dosing data. Before increasing the long, verify readout timing and whether proposed infrequent dosing translates into sustained weight loss and payer access.